Answers are grounded in this paper and cite their sources.
Long-term results show seladelpar treatment improves outcomes in primary biliary cholangitis patients, indicating its potential as a therapeutic option.
Introduction: ASSURE (NCT03301506) is an ongoing, open-label, long-term, Phase 3 trial of seladelpar — a selective PPARδ agonist — in patients (pts) with primary biliary cholangitis rolling over from the Phase 3, placebo-controlled RESPONSE trial (NCT04620733) or with prior participation in legacy trials (Phase 3 ENHANCE [NCT03602560], CB8025-21629 [NCT02955602], CB8025-31731 [NCT03301506], CB8025-21838 [NCT04950764]). The parent studies required an inadequate response or intolerance to first-line ursodeoxycholic acid.
No takes yet. Share an insight, caveat, or question.
Lawitz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: